Kornimate/medical-research-clean huggingface dataset:
effects of inspiratory muscle training in pulmonary hypertensive patient

Conditions: Inspiratory Muscle Training

Summary: although the progressive nature of pulmonary hypertension (ph), including the impairment of respiratory muscle function, studies have demonstrated beneficial effects of physical exercise on the functional limitations caused by the disease in this population, being an important collaborator to the conventional drug therapy.respiratory muscle training (rmt) improves functional capacity and quality of life (qol) in patients.a randomized controlled trial was conducted to evaluate the effectiveness of this protocol on respiratory muscle strength and endurance, functional capacity. 18 subjects were allocated in 2 groups, group a was control group and group b was experimental group. group a or control group received deep breathing exercises. group b received 30 minutes of imt 6days weekly for 2 weeks by using a pressure threshold device. the purpose of this study was to investigate the effects of inspiratory muscle training (imt) in pah. to evaluate effectiveness of imt mouth pressure device ,functional capacity using 6 minute walking test (6mwt)health assessment via sf 36 questionnaire were used before and after training protocol.


Eligibility criteria:
inclusion criteria: age group of 40 to 70 years. * both male and females will be included. * patients with a diagnosis of ph (papm ≥ 25mmhg and paop \<15mmhg); * clinically stable with augmented and unchanged daily medication therapy in the last three months; subjects who agree to contribute in the research by signing a free and knowledgeable consent form. exclusion criteria: * copd * severe ischemic heart disease * left heart failure; * cor pulmonale * cognitive disorders; * orthopedic problems; e.g;fracture in thoracic region. * emergency or elective surgical intervention during the protocol; * recent viral infections;
sedation of mechanically ventilated critically ill patients: midazolam versus dexmedetomidine

Conditions: Mechanically Ventilated Patients; Sedation; Dexmedetomidine; Midazolam

Summary: the aim of this prospective randomized study is to compare the safety and efficacy of two strategies for sedation of critically ill patients submitted to mechanical ventilation: continuous intravenous infusion of dexmedetomidine versus intravenous bolus of midazolam. the two groups will be compared as to the incidence of of delirium, evaluated with the confusion assessment method for icu (cam-icu) and the percentage of time within the target sedation using the richmond agitation-sedation scale (raas).eligible patients will be 18 years or older intubated and mechanically ventilated for less than 48 hours prior to start of study drug and anticipated ventilation duration of at least 48 hours. calculated sample size is 146 patients (73 patients in each group)


Eligibility criteria:
inclusion criteria: * adult mechanically ventilated, critically ill patients exclusion criteria: * pregnancy or lactation, severe liver disease, hearth rate less than 50, hypotension despite volemic repletion and vasoactive drug

Keywords: dexmedetomidine midazolam sedation mechanical ventilation critically ill patients
biomarker study after initiation of treatment with fingolimod (fty720) in patients with relapsing-remitting multiple sclerosis

Conditions: Relapsing-remitting Multiple Sclerosis

Summary: the purpose of this study is to investigate which changes in immunological biomarkers under treatment with fingolimod in patients with relapsing-remitting multiple sclerosis can be detected.


Eligibility criteria:
inclusion criteria: * subjects with relapsing forms of ms defined by 2005 revised mcdonald criteria * patients with expanded disability status scale (edss) score of 0-6.5 exclusion criteria: * patients with a manifestation of ms other than relapsing remitting ms * patients with a history of chronic disease of the immune system other than ms such as known immunodeficiency syndrome * history or presence of malignancy in the last 5 years * diabetic patients with moderate or severe non-proliferative diabetic retinopathy or proliferative diabetic retinopathy and uncontrolled diabetic patients * diagnosis of macular edema during screening phase * patients with active systemic bacterial, viral or fungal infections * negative for varicella-zoster virus igg antibodies at screening * patients who have been treated with cladribine, cyclophosphamide or mitoxantrone at any time * history of cardiovascular disorder * women of child-baring potential and inadequate contraception other protocol-defined inclusion/exclusion criteria may apply

Keywords: multiple sclerosis rrms relapsing-remitting fingolimod biomarkers
to assess the effect of scd-044 treatment on moderate to severe plaque psoriasis

Conditions: Moderate to Severe Plaque Psoriasis

Summary: this is a multicenter, randomized, double-blind, placebo-controlled study in subjects with moderate to severe plaque psoriasis.

this is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to determine the effect of scd-044 in subjects with moderate to severe plaque psoriasis.

Eligibility criteria:
inclusion criteria: 1. males and non-pregnant non-lactating females with a diagnosis of predominantly plaque psoriasis for ≥ 6 months as determined by subject interview and confirmation of diagnosis through physical examination by investigator. 2. aged at least 18 years. 3. subjects with no history of active tb or symptoms of tb exclusion criteria: 1. subjects with non-plaque forms of psoriasis-like erythrodermic psoriasis, pustular psoriasis, medication-induced, or medication exacerbated psoriasis or new-onset guttate psoriasis. 2. subjects who have anticipated the requirement of topical therapy, phototherapy, or systemic therapy for psoriasis during the trial. 3. subjects with history or presence of uveitis
esp study: a study to assess the effect of adding fuzeon (enfuvirtide) to an antiretroviral regimen in fuzeon-naive patients with sustained hiv viral suppression.

Conditions: HIV Infections

Summary: this 2 arm study will assess the immunological benefits of adding fuzeon to an antiretroviral regimen in hiv-infected, fuzeon-naive patients with a cd4 cell count \<250 cells/mm3 and an hiv rna viral load \<400 copies/ml. eligible patients will be randomized to receive fuzeon 90mg bid sc in addition to their current antiretroviral therapy, or to continue their current antiretroviral therapy alone. the anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age; * documented chronic hiv infection; * currently receiving a stable antiretroviral regimen; * cd4 cell count \<250 cells/mm3; * hiv rna viral load \ 12 months. exclusion criteria: * prior exposure to fuzeon; * prior non-adherence to antiretroviral treatment regimens; * active opportunistic infection; * currently taking, or anticipated to take during the study, any immunomodulator.

Keywords: treatment experienced
pain neuroscience education in total knee arthroplasty

Conditions: Total Knee Replacement

Summary: to determine if education about pain given prior to knee arthroplasty will result in better outcomes following surgery

to determine if a preoperative pain neuroscience education (pne) program would result in superior outcomes compared to usual preoperative education for total knee arthroplasty (tka). patients will receive traditional hospital preoperative tka program (usual care group) or receive the same program plus an additional 30-minute pne program (experimental group). pre and post measurements at 1, 3 and 6 months for pain, function, fear of movement and pain catastrophization. we will also compare opioid usage, healthcare expenses and patient satisfaction between groups.

Eligibility criteria:
inclusion criteria: * be scheduled to have a tka and their standard preoperative tka education program, indicate their willingness to participate in the study, ability to read and understand english, as the study included the use of an educational booklet, and be able and willing to complete outcome data for 6 months after tka exclusion criteria: * because all potential participants for this study had been screened and cleared for their orthopedic surgery, the only exclusion criterion was an unwillingness to participate in the study and having had a previous tka or scheduled for a bilateral tka.
photobiomodulation therapy in persons with multiple sclerosis

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: this study will test whether photobiomodulation therapy improves muscle endurance and decreases inflammation in persons with relapsing-remitting multiple sclerosis. we will also investigate mechanisms for any improvements.

persons with multiple sclerosis (ms) ms commonly experience muscle weakness and fatigue which may contribute to the commonly reported symptomatic fatigue. photobiomodulation therapy (pbmt) induced with light in the visible red to near infrared (vis/nir) region of the spectrum (600-1000 nm) can stimulate cytochrome c oxidase and improve mitochondrial function. pbmt is an emerging therapeutic modality for soft tissue injury, chronic inflammation, neurodegeneration , and retinal diseases. pbmt has also been used to enhance muscle endurance, strength and recovery in healthy adults. we propose that in persons with ms, pbmt will 1) enhance regional muscle endurance after acute treatment and 2) enhance functional endurance after extended treatment. we will also test to determine if improvements are due to central or peripheral neuromuscular or cardiovascular mechanisms. final, we will explore if regional pbmt can result in systemic anti-inflammatory effects.

Eligibility criteria:
inclusion criteria: 1. relapsing remitting ms, 2. independent or ambulatory with minimal aid. 3. must be able to move foot (ankle dorsiflexion) at least moderately forcibly against gravity (manual muscle test score 3-5) 4. subjects must be able to walk for 6 minutes independently with no or minimal use of an assistive device. exclusion criteria: 1. no noticeable left right ankle strength asymmetry 2. no exacerbations (ms attacks) or immunosuppressive therapy use within the previous 6 months 3. no concurrent infection or known cardiovascular disease including having a pacemaker; or other serious medical co-morbidity including metabolic, mitochondrial, autoimmune, diseases or other co-existing neurologic conditions. 4. not involved in any clinical trial or other research that could confound results. 5. must not be pregnant 6. must not have an active diagnosis of cancer
study of nivolumab for advanced cancers in india

Conditions: Non-Small Cell Lung Cancer (NSCLC); Non-Small-Cell Lung Carcinoma; Nonsmall Cell Lung Cancer; Kidney Cancer; Kidney Neoplasms; Renal Cancer; Renal Neoplasms

Summary: this is a study of nivolumab in participants with advanced non-small cell lung cancer or kidney cancer in india.


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * locally advanced or metastatic non-small cell lung cancer (nsclc) after prior chemotherapy or advanced renal cell carcinoma (rcc) after prior therapy * eastern cooperative oncology group (ecog) performance status of ≤ 1 * prior radiotherapy or radiosurgery must have been completed at least 2 weeks prior to randomization exclusion criteria: * participants with untreated, symptomatic central nervous system (cns) metastases * participants with carcinomatous meningitis * participants with active, known or suspected autoimmune disease * participants with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications * other active malignancy requiring concurrent intervention other protocol defined inclusion/exclusion criteria could apply
effects of deep touch pressure on emergence agitation in pediatric patients

Conditions: Deep Touch Pressure

Summary: the goal of this clinical trial is to determine if deep touch pressure (dtp) can reduce emergence agitation (ea) in pediatric patients aged 3 to 10 years undergoing tonsillectomy and adenoidectomy under general anesthesia. the main questions it aims to answer are: does deep touch pressure (dtp) using a compression vest reduce the incidence of emergence agitation (ea) in the recovery room? does dtp reduce the severity of ea, as measured by the pediatric assessment of emergence delirium (paed) scale? researchers will compare: intervention group: pediatric patients who receive dtp using the huggy compression vest during the recovery period. control group: pediatric patients who receive standard postoperative care without dtp. participants will: be randomly assigned to either the intervention group (dtp) or the control group. undergo standard general anesthesia for tonsillectomy and adenoidectomy. wear the huggy compression vest if assigned to the intervention group. be monitored for emergence agitation using the paed scale and flacc pain scale in the recovery room. receive rescue medication (nalbuphine) if severe ea occurs. this study will help determine if dtp can be used as a safe and effective non-pharmacological method to reduce emergence agitation in pediatric patients.


Eligibility criteria:
inclusion criteria: * pediatric patients aged 3 to 10 years scheduled for tonsillectomy and adenoidectomy under general anesthesia. exclusion criteria: * emergency surgery. * known neurological disorders (e.g., epilepsy, cerebral palsy). * skin disorders or injuries on the chest or upper body that prevent safe use of the compression vest (huggy). * history of severe psychiatric disorders (e.g., autism spectrum disorder, severe anxiety disorder). * history of severe allergic reactions to anesthesia. * any condition that, in the investigator's judgment, makes the patient unsuitable for the study.
quality improvement study on operative consent forms

Conditions: Quality Improvement; Informed Consent

Summary: a quality improvement project was undertaken to improve the completion of operative consent forms within a uk hospital plastic surgery department. four weekly interventions were made which were accompanied by four further data collection cycles.

background royal college of surgeons guidelines exist on the importance of full, accurate and legible completion of consent forms as a key part of the process of gaining informed consent. in addition to this, consent forms serve as an important medico-legal document to protect clinicians and patients should problems arise. it is therefore in all parties' interests that they are correctly completed. it was noted that consent forms within the royal london hospital plastic surgery department were often not correctly completed. a quality improvement project was undertaken to improve the completion of consent forms within the department. materials and methods common problem areas on consent forms were identified and qi methodology was used to design the study including selection of appropriate outcome, process and balancing measures. baseline information on completion of: 1) patient details, 2) consultant details, 3) legibility, 4) use of abbreviations in description of operation/complications, and 5) patient signatures was collected. four weekly interventions were made which were accompanied by four further data collection cycles. a further re-audit took place 4 months following the completion of the project to establish whether improvements had been sustained.

Eligibility criteria:
inclusion criteria: * operative consent form 1 or consent form 2 completed within the royal london hospital plastic surgery department within one week of the previous intervention. exclusion criteria: * all other consent forms
group therapy program for women with physical disabilities

Conditions: Depressive Symptoms

Summary: more women with disabilities (30%) report "feelings such as sadness, unhappiness, or depression that prevent them from being active" compared to women without disabilities (8%). the contexts of the lives of wpd, which often include high rates of poverty, architectural and attitudinal barriers, and higher vulnerability to violence and abuse, contribute to this mental health disparity. to help address this disparity, the overall goals of this pilot study are to: 1)1. develop a cognitive behavioral group therapy intervention to address the specific needs of wpd who experience depressive symptoms; and 2. pilot-test the intervention to preliminarily evaluate its efficacy using a mixed-methods approach. the proposed and revised study outcomes were derived from our previous work with wpd as well as from feedback obtained from community meetings conducted since our last submission of this proposal. a pilot of the modified intervention with a total of 90 participants will be conducted using a using a wait list control design. the decision to use a wait list control design was made jointly with our community partners to ensure that all wpd participating in the study have access to the intervention.

the project will use a longitudinal mixed method research design. phase i will utilize focus groups conducted with wpd to support development of the group therapy program. phase ii will evaluate the efficacy of the intervention using a randomized design. measures to protect human subjects include development of detailed safety and referral protocols including 24 hour access to emergency mental health assessment and intervention as needed.

Eligibility criteria:
inclusion criteria: * women with physical disabilities age 18 and older who require some form of accommodation and experience significant depressive symptoms as defined by a cut off score of 16 or greater on the ces-d. exclusion criteria: * women currently receiving other psychotherapy treatment * women who are psychotic or have significant cognitive impairment * women who are actively suicidal with intent and plan * women who have discontinued or initiated antidepressant medications within an 4 week time period.

Keywords: women with physical disabilities secondary conditions depression cognitive behavioral therapy consumer control
the cartilage and muscle thickness on knee pain in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis; Knee Pain Chronic; Muscle Loss; Cartilage Degeneration

Summary: the knee pain status of the patients who are followed in the rheumatology special branch of the physical medicine and rehabilitation outpatient clinic and who meet the inclusion criteria will be questioned. in patients with or without knee pain, the cartilage thickness measurement of the knee joint will be measured from 3 points by ultrasound. at the same time, quadriceps and hamstring muscle thickness measurements of the patients will be made from the midpoints where the muscle thickness is the highest. the physician who performed the ultrasonographic measurements of the knee pain status of the patients does not know.


Eligibility criteria:
inclusion criteria: * rheumatoid arthritis \> diagnosed for 1 year * -female gender * -the patient has been in remission or low disease activity for at least 3 months * -be able to ambulatory * -no significant deformity in the lower extremity joints exclusion criteria: * patient with active arthritis or high disease activity * - significant deformity of the lower extremity joints and inability to ambulate * -pregnant patient * - presence of malignancy * - patient with a severe psychiatric disorder and difficulty in cooperation * - presence of cardiovascular and pulmonary comorbidities that will prevent exercise * -male gender
engagerx with integrated self-measurement of blood pressure

Conditions: Hypertension

Summary: this pilot study will support use of engagerx_smbp for 70 patients in the ucsf general internal medicine practice. the goals of the pilot will be to assess usability and satisfaction of both patients and clinicians, and to describe bp-related process metrics and outcomes including time to intensification of bp medications and/or bp control.

engagerx is a programmable clinical decision support app that clinicians can access within the context of their electronic health record (ehr), and it can be connected with other technologies. we are integrating engagerx with caresimple, a company that provides a cellular-enabled bp device that patients can use for smbp. caresimple devices are fda-cleared, can be shipped directly to patients, used by patients right out of the box (after installing batteries), and then deliver the smbp measurements directly to the caresimple cloud platform. there is no requirement to "sync" the device, and no need for patients to have a smartphone or set up an account or sign into anything. caresimple supports a dashboard and portal that allows authorized users to sign in and access measurements for a patient, but this amounts to another barrier for clinicians to access the measurements; our integration with engagerx will 1) allow clinicians to initiate smbp monitoring for a patient with the click of a button (after confirming their shipping address and preferred language); 2) automatically register the patient in the caresimple system, which triggers caresimple to mail the patient the bp monitor device with instructions; and 3) automatically push the caresimple smbp measurements to engagerx so they are available the next time the clinician opens engagerx. the smbp measurements will be used with engagerx's internal algorithm, along with office bp measurements, to recommend bp management decisions to clinicians. we believe this integrated system, which we will refer to as engagerx_smbp, will make smbp easy for clinicians and patients. we would like to determine if this system is truly easy to use for clinicians and providers, and whether it appears to facilitate the bp-related processes of care required for controlling hypertension.

Eligibility criteria:
inclusion criteria: * adult patient (18+ years old) with uncontrolled bp in an office visit * lowest sbp\>140 or lowest dbp\>90 during the visit at one of the mt. zion general internal medicine practices * speaks english or spanish exclusion criteria: * if patient is unlikely to be able to use a home bp monitor * cannot understand the verbal consent